Summary:
Click image to enlarge
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to 49 years of age without pre-existing risk factors for serious complications from influenza infection
Criteria:Eligible participants include healthy adult men and women aged 18 to < 65 years. Key inclusion criteria include body mass index (BMI) of 18.0 kg/m2 to 35.0 kg/m2 , inclusive, as well as no clinically significant findings from physical examination, 12-lead electrocardiogram (ECG), vital signs, and laboratory values.
Key exclusion criteria include prior or planned receipt of any influenza vaccine for the upcoming influenza season, history or clinical evidence of conditions considered high risk for developing influenza-related complications, or any other clinically significant medical condition.
Qualified Participants May Receive:
Subjects will recive up to $5,000 in breakdowns.